Company Overview and News

0
DoTr targets common station contract award next month

18h bworldonline
THE Department of Transportation (DoTr) said the contract for the construction of the Metro Rail Transit (MRT)-Light Rail Transit (LRT) common station project is scheduled to be awarded by August.
FPAFY SMCP1 MPCIY PXMFF SMGBY 0142 SMGBF SMPH SMC2B SMC2A PX FPAFF SMC SMC2D SMC2C MPI MPCFF SMC2F SPHXY SMC2E SPHXF SPHZF PXMFY

0
GT Capital’s ProFriends inks deal to sell land in Cavite to MPIC arm

2018-07-16 bworldonline
A PROPERTY UNIT of GT Capital Holdings, Inc. has sealed a deal with Metro Pacific Investments Corp.’s (MPIC) logistics arm to sell its Cavite property for P1.02 billion.
GTCXY PSKXF GTCAP PX MPCFF MPCIY MPI PXMFF PHSXY PSE PXMFY

0
DPWH pushes for CALAX partial opening by Dec.

2018-07-15 bworldonline
THE Department of Public Works and Highways (DPWH) is pushing for the completion the Laguna segment of Metro Pacific group’s Cavite-Laguna Expressway (CALAX) project by December despite construction delays caused by heavy rains.
PX MPCFF MPCIY MPI PXMFF PXMFY

0
LRMC pushes for LRT-1 fare hike

2018-07-12 bworldonline
THE operator of Light Rail Transit Line 1 (LRT-1) continued to push for a P5 fare hike, saying this would allow the company to proceed with the construction of the train line’s extension to Cavite.
FPAFY PX FPAFF MPCFF MPCIY MPI PXMFF PXMFY 0142

0
Preliminary work on NLEx-SLEx connector road to start by Q4

2018-07-09 bworldonline
PRELIMINARY construction work for the connector road that will link the Metro Pacific group’s North Luzon Expressway (NLEx) and San Miguel Corp.’s South Luzon Expressway (SLEx) is expected to start by the fourth quarter of this year, Metro Pacific Tollways Corp. (MPTC) said.
SMCP1 MPCIY PXMFF SMGBY SMGBF SMC2B SMC2A PX SMC SMC2D SMC2C MPI MPCFF SMC2F SMC2E PXMFY

0
MPTC starts work on Cebu-Cordova expressway

2018-07-05 bworldonline
CEBU CITY — A Metro Pacific Tollways Corp. (MPTC) unit began on Thursday the construction of a toll bridge that will connect Mactan island to mainland Cebu.
PX MPCFF MPCIY MPI PXMFF PXMFY

0
Go signal for PT Nusantara tender offer seen by August

2018-07-04 bworldonline
METRO PACIFIC Tollways Corp. (MPTC) targets to get the greenlight from Indonesian regulators for the conduct of a tender offer in favor of minority shareholders of infrastructure firm PT Nusantara Infrastructure Tbk by August.
FPAFY PX FPAFF PXMFF PXMFY 0142

0
MPTC subsidiary gains control of Indonesian firm

2018-07-03 bworldonline
A UNIT of Metro Pacific Tollways Corp. (MPTC) gained control of Indonesian infrastructure firm PT Nusantara Infrastructure Tbk after increasing its stake to more than 50%.
PX MPCFF MPCIY MPI PXMFF PXMFY

9
Indie power producer GBP shifts to sustainable energy

2018-06-29 bworldonline
REGIONAL independent power producer Global Business Power Corp. (GBP) is shifting to provide sustainable energy solutions in a move to adapt to the current landscape in the sector.
PX MPCFF MPCIY MPI PXMFF PXMFY ACR

5
Building a legacy of excellence

2018-06-29 bworldonline
From a small company with less than 10 employees in 2009, Mundo Builders, Inc. continuously grows and gains popularity for its distinctive, one-on-one approach. Within nine years of operations, the firm has become instrumental in designing and creating the world of its clients from diverse industries, with quality workmanship and professionalism. As it moves forward, Mundo Builders not just leaves footprints of yesterday’s dreams but as well as a legacy for future generations.
UBNC WU PX PXMFF PXMFY

9
SEC approves NLEX fund-raising

2018-06-20 bworldonline
NLEX Corp. has secured clearance from the Securities and Exchange Commission (SEC) for its shelf registration of up to P25 billion in fixed rate bonds.
FPAFY PX FPAFF MPCFF MPCIY MPI PXMFF PXMFY 0142

10
Work on LRT-1 Cavite extension to start in Oct.

2018-06-18 bworldonline
LIGHT RAIL Transit Line 1 (LRT-1) operator Light Rail Manila Corp. (LRMC) said it expects to begin the construction of the first phase of the Cavite extension project by October.
FPAFY PX FPAFF MPCFF MPCIY MPI PXMFF PXMFY 0142

16
MPIC logistics unit to build warehouses in Cavite

2018-06-18 bworldonline
THE logistics unit of Metro Pacific Investments Corp. (MPIC) will be setting aside P8 billion for the development of warehouses in Cavite, as it aims to become a leading player in the logistics space.
FPAFY GTCXY GTCAP PSKXF MPCIY PXMFF 0142 PX FPAFF MPI MPCFF PHSXY PSE PXMFY

9
MPIC unit completes deal for Vietnam water firm

2018-06-12 bworldonline
A UNIT of Metro Pacific Investments Corp. (MPIC) has completed the acquisition of a 49% stake in Vietnamese company that will allow its expansion into the Southeast Asian country’s industrial water concessions, the listed company told the stock exchange on Monday.
PX MPCFF MPCIY MPI PXMFF PXMFY

9
Cavitex widening, Marina flyover sees early completion

2018-06-01 bworldonline
ADVANCED completion in July is being targeted for the Manila-Cavite Expressway (Cavitex) road-widening project and the construction of the southbound Marina flyover.
PX MPCFF MPCIY MPI PXMFF PXMFY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...